Home Data Calendar Blog

REGN

Tables

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Weighted Average Number Of Diluted Shares Outstanding NA113.40113.90114.00NA112.80114.00113.10NA113.90110.80110.50NA113.90117.90115.10NA114.20114.60115.50NA115.09114.48114.91NA117.03116.14115.11NA116.47116.23114.23NA115.94115.26114.52NA117.42113.03112.15NA116.71111.06109.37NA115.83110.17107.73NA91.0590.4489.16NANANANA
Weighted Average Number Of Shares Outstanding Basic NA106.30107.00107.10NA106.90107.90106.80NA106.20105.00105.40NA105.50109.60109.80NA109.40109.20108.90NA108.03107.80107.65NA106.71106.03105.57NA104.83104.63104.29NA103.35102.89102.23NA100.80100.3998.71NA98.2397.7096.88NA95.0194.5993.45NA91.0590.4489.16NANANANA
Earnings Per Share Basic 10.899.489.057.6411.2112.317.909.1220.9815.3729.5110.5810.907.988.195.697.256.121.774.237.585.505.124.441.623.643.662.362.412.531.881.591.492.041.890.741.090.790.920.660.981.440.891.024.922.020.810.12-0.58-0.68-0.69-0.49NANANANA
Earnings Per Share Diluted 10.208.898.507.1710.4911.667.478.6119.6814.3327.9710.0910.247.397.615.436.935.861.683.997.155.174.824.161.503.323.342.162.192.271.691.451.341.821.690.660.960.700.820.580.861.250.790.904.081.720.700.11-0.58-0.68-0.69-0.49NANANANA

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Revenue From Contract With Customer Excluding Assessed Tax 3434.303362.703158.103162.103414.402936.202857.202965.104951.703452.805138.502528.702422.902294.001952.001828.202169.502048.401933.701711.801927.801663.501608.021511.501582.401500.671470.121319.001226.831220.121212.631200.851098.081137.42998.62869.61802.33725.79665.70625.74610.41597.03457.64439.66414.60427.69304.40231.79122.98102.83107.81112.20133.68105.98115.89103.53
Revenues 3434.303362.703158.103162.103414.402936.202857.202965.104951.703452.805138.502528.702422.902294.001952.001828.202169.502048.401933.701711.801927.801663.501608.021511.481582.451500.671470.121318.991226.831220.121212.631200.851098.081137.42998.62869.61802.33725.79665.70625.74610.41597.03457.64439.66414.60427.69304.40231.79122.98102.83107.81112.20133.68105.98115.89103.53
Costs And Expenses 2461.402251.702141.602215.402267.601712.501747.301706.602312.001605.601791.301416.001255.901240.901295.601128.101493.801309.901618.101231.801209.701036.57985.83944.251043.64940.75919.80888.45879.82857.32921.00871.54867.00745.00653.76586.06586.53543.07443.29439.80398.34360.23299.54286.61268.93225.32216.92209.59168.38161.29168.13153.19146.45138.07139.61132.41
Research And Development Expense 1177.201075.301085.301101.201043.10911.30794.30843.80785.60665.40714.20742.90744.50684.60722.00583.90683.10663.401048.30641.80601.25556.97529.29498.59527.98529.75509.98507.44479.21543.05559.93470.11461.21425.92390.33343.11351.75337.73294.50287.38268.14224.04187.46180.30181.02158.29147.37138.86129.04127.92143.15129.39125.21122.04124.53117.47
Selling General And Administrative Expense 737.70640.50652.00601.10660.50529.10476.30450.00559.60445.00414.70405.60303.50326.90348.30367.30586.80419.90417.30410.80491.31369.23364.88330.77409.91306.77306.91296.85325.94270.05292.04289.68294.95209.99174.59158.99175.31149.75102.41108.8582.0897.6172.4677.2657.7446.8847.7058.4336.3532.9224.5923.4120.6415.6614.6814.22
Operating Income Loss 972.901111.001016.50946.701146.801223.701109.901258.502639.701847.203347.201112.701167.001053.10656.40700.10675.70738.50315.60480.00718.06626.92622.19567.23538.81559.93550.31430.54347.00362.80291.63329.31231.08392.42344.86283.55215.80182.72222.41185.94212.07236.80158.10153.05145.67202.3687.4822.20-45.40-58.46-60.32-40.98-12.78-32.09-23.72-28.88
Interest Expense 18.3017.8018.9018.0017.4015.3013.1013.6014.1014.2014.4014.6014.8026.309.706.106.707.808.007.707.357.496.926.446.026.185.407.50NANANANA3.611.722.756.176.359.2310.1811.6111.6611.7411.3711.6811.4911.4111.2411.169.464.064.053.722.462.232.342.08
Income Tax Expense Benefit -12.00103.00114.5040.20127.60194.10111.1087.60274.40184.40653.90137.8075.40156.2021.6044.0097.8098.9031.6085.00-144.1941.21104.66107.42381.25177.29138.11183.3688.41101.0896.04164.4172.30182.89133.35200.5099.6396.36110.38109.82101.3584.3860.3242.96-335.80NA0.00NA-0.610.56-0.86-0.220.000.000.000.00
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax NANANANA0.000.000.001.000.200.200.300.200.300.200.00-1.400.20-0.30-1.40-1.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Other Comprehensive Income Loss Net Of Tax NA20.90-16.1057.20NA-51.30-53.70-143.90NA-6.20-0.50-13.10NA-4.7044.60-30.20NA0.7013.0015.10NA1.104.10-9.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Net Income Loss 1159.601007.80968.40817.801197.101315.70852.10973.502229.001632.203098.901115.201149.20842.10897.30624.60792.00669.60193.10461.10820.40594.65551.41477.98173.52388.32387.74248.93253.12264.80196.22165.74154.99210.40194.6476.02110.1879.7292.7365.4496.81141.3187.3898.87470.41191.4776.7411.65-53.44-62.37-62.51-43.45-14.60-33.88-25.47-30.52
Comprehensive Income Net Of Tax 1255.501028.70952.30875.001233.401264.40798.40829.602193.301626.003098.401102.101147.70837.40941.90594.40796.60670.30206.10476.20818.62595.75555.39468.34150.32409.80395.98255.89243.17256.70197.06161.53155.84198.97165.8971.67135.53102.3595.5368.1098.47141.8885.5998.40471.14191.9475.7112.18-53.57-63.19-61.23-43.13-16.91-33.74-26.50NA

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Assets 33080.2032163.3030657.5030059.9029214.5027677.8027205.8026348.7025434.8023671.5021485.9017772.2017163.3016084.0014428.7015757.5014805.2013939.3013173.6012854.8011734.5010805.619951.989372.708764.298701.228106.377817.366973.476828.026204.915904.465609.135182.914526.974198.573871.833739.423456.083260.402951.012640.412378.262276.002080.491660.621457.501350.161323.58983.031046.861074.291089.43NANANA
Liabilities 7107.107258.906639.606564.706550.506239.006518.006434.006666.006413.506358.605795.206138.005958.505371.303624.503715.503434.903417.703410.102977.202937.312765.552805.052620.212649.622585.642951.342524.222336.772128.402139.381954.301886.051188.511227.141329.501187.631087.241049.15998.94950.24884.92869.65835.11854.59862.84846.13837.85554.78568.83556.20561.62NANANA
Liabilities And Stockholders Equity 33080.2032163.3030657.5030059.9029214.5027677.8027205.8026348.7025434.8023671.5021485.9017772.2017163.3016084.0014428.7015757.5014805.2013939.3013173.6012854.8011734.5010805.619951.989372.708764.298701.228106.377817.366973.476828.026204.915904.465609.135182.914526.974198.573871.833739.423456.083260.402951.012640.412378.262276.002080.491660.621457.501350.161323.58983.031046.861074.291089.43NANANA
Stockholders Equity 25973.1024904.4024017.9023495.2022664.0021438.8020687.8019914.7018768.8017258.0015127.3011977.0011025.3010125.509057.4012133.0011089.7010504.409755.909444.708757.307868.307186.436567.646144.086051.595520.744866.024449.244491.254076.513765.083654.843296.873338.462971.432542.322551.792368.842211.251952.081690.171493.341406.351245.38806.02594.66504.02485.73428.25478.03518.09527.82348.06371.22386.27

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Assets Current 19479.2018634.8016923.0016909.2015884.1015428.6015529.9014306.0014014.9013775.4013337.6010055.109779.109097.607860.208644.107689.107109.106651.006928.606447.605719.584814.924544.734335.034135.743860.053669.263180.193501.693209.223133.382915.092675.642283.342310.712167.462200.511918.691871.051796.931634.161561.361307.121206.01948.60769.19696.91652.88339.87413.27325.50357.62NANANA
Cash And Cash Equivalents At Carrying Value 2730.002152.301937.203916.303105.903491.303395.103345.702885.603432.402072.201437.902193.701573.001992.202208.201617.801384.801045.501708.501467.701087.84917.881019.49812.73792.07744.31811.77535.20920.36646.51604.21809.10654.59390.55507.91648.72646.55600.13461.86535.61263.21381.68180.36230.28119.00171.94394.58483.61206.40254.31135.38112.57325.29112.00117.31
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 2737.802160.201949.703928.803119.403504.803408.603359.202898.103444.902084.701450.402207.301586.602004.702220.701630.301397.301058.001721.001480.201100.34930.381031.99825.23804.57756.81824.27547.70NANANA809.10NANANANANANANANANANANANANANANANANANANANANANANA
Marketable Securities Current 8114.807761.306990.505043.404636.403530.404171.303704.902809.102355.201838.602065.901393.301452.901152.001795.201596.501493.101624.201523.901342.201104.31765.64605.46596.85586.88523.54495.31503.48488.03398.66244.97236.12241.06213.69234.26251.76395.65216.77186.28158.38182.11155.83127.3577.82143.55129.0837.7143.3339.1055.3791.06136.80NANANA
Accounts Receivable Net Current 5667.305584.505121.305118.605328.705548.305161.404839.006036.505452.006998.604173.003111.503092.501991.002063.102100.002027.701920.201728.401723.701665.741534.321531.941538.641532.691420.401339.791343.371332.071431.971450.571152.491088.211071.661015.96739.38673.91664.08801.77787.07855.84767.87703.86593.21506.68349.64159.4628.253.662.923.7713.51NANANA
Inventory Net 2580.502562.002507.702424.702401.902412.202218.501991.501951.302053.801983.902164.701916.601801.601640.901480.901415.501344.301317.201208.801151.201039.68928.55820.40726.14641.59554.32466.58399.36345.62316.07303.29238.58190.67171.27133.86128.86120.32109.9086.5570.3563.2957.1643.9828.6429.5710.506.203.50NANANANANANANA
Prepaid Expense And Other Assets Current 386.60574.70366.30406.20411.20446.40583.60424.90332.40482.00444.30213.60160.80230.60263.80226.60387.10226.90208.20182.20243.30284.81163.60155.45224.97143.76193.33146.06130.53103.8196.02115.69163.5089.4943.1034.1071.4961.7360.6752.2596.14156.84108.9197.1456.6684.7832.7926.2722.9015.9319.03NA15.14NANANA
Available For Sale Securities Debt Securities 12533.9012620.4012290.0010051.3010018.208369.609712.109750.208397.206614.904337.604607.203689.103550.402934.504469.604234.504176.004094.803733.003009.202834.212724.762358.372020.561826.141527.851408.361318.521203.72917.82778.76836.82894.83757.16627.98613.10789.56760.62717.43547.10509.73326.86479.53351.56461.64422.99296.90322.14301.33310.38NA510.28NANANA

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Amortization Of Intangible Assets NANANANA37.6015.60NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Property Plant And Equipment Net NANANANANA3704.203637.703556.403482.203395.703358.503262.603221.603138.303031.402944.602890.402771.402676.602612.802575.802524.452461.612394.732358.612274.532261.702277.032083.421872.171772.921666.391594.121475.121326.111110.60974.31818.97707.32600.86526.98453.89419.65392.38379.94372.92372.28369.96367.95363.91361.88357.42347.45NANANA
Intangible Assets Net Excluding Goodwill 1038.601017.20953.00928.70915.50804.10NANA6.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Finite Lived Intangible Assets Net NANANANANA804.10NANA6.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Other Assets Noncurrent 444.10409.90393.20349.60336.40320.20269.90262.00222.80145.90142.90145.70168.10168.80175.50161.20144.70137.90139.80144.30127.40125.2085.6778.9877.8736.6236.9637.0920.2920.706.715.795.814.584.144.473.033.428.885.345.334.4115.2120.0823.1018.3219.5720.3919.1413.0212.2910.236.79NANANA
Available For Sale Debt Securities Amortized Cost Basis 12636.0012843.5012539.4010280.8010320.108716.309994.409965.108428.706600.904315.504584.103649.203508.302890.304478.004206.304148.904073.703730.203026.602851.522743.03NA2027.27NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Liabilities Current 3423.403598.603104.403100.103141.302879.203033.903007.603932.503714.803732.403217.802697.402337.803702.402055.202096.601765.401713.101511.401442.801417.231331.191265.741135.481138.631029.021308.271241.49961.18951.56919.72811.16734.99601.54536.13654.66410.20351.58305.07298.83268.73203.80197.24163.55178.57183.22160.39148.27133.24135.87112.25109.06NANANA
Accounts Payable Current 606.60536.60547.30599.50589.20NANANA564.00NANANA475.50NANANA418.10NANANA218.20NANANA178.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Accounts Payable And Accrued Liabilities Current 2357.90NANANA2074.20NANANA2206.80NANANA1521.80NANANA1086.80NANANA772.10NANANA815.08818.43716.361061.78879.10714.92759.64733.28644.11577.43529.50462.76484.23337.98283.38237.94250.90219.14153.83145.41111.34124.22126.77106.7295.6278.8981.6758.6053.66NANANA
Other Accrued Liabilities Current 666.70NANANA637.50NANANA383.90NANANA329.60NANANA301.30NANANA164.60NANANA129.4184.6979.3799.05103.5183.46107.03102.6485.64126.0772.2097.88117.3055.6848.5438.1129.0238.3219.9522.3719.5722.2015.2218.2014.138.217.81NA6.44NANANA
Taxes Payable Current NANANANA0.30NANANA326.30NANANA19.50NANANA49.40NANANA20.80NANANA0.23126.6123.24450.81235.78155.49170.27144.080.00NANANANANANANANANANANANANANANANANANANANANANANA
Contract With Customer Liability Current 458.90417.30381.10426.30477.90547.20566.30491.30442.00507.80520.00464.90577.70NANANA591.70NANANA452.50NANANA320.10NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Long Term Debt Noncurrent 1982.901982.601982.201981.801981.401981.101980.701980.401980.001979.601979.201978.901978.501978.30NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Other Liabilities Noncurrent 854.10832.40716.80677.30638.00598.60724.70692.50680.20662.60596.30571.50687.10454.00457.90321.50286.00273.00267.90376.30361.70194.03190.02169.92152.07125.22115.92106.25100.39135.70119.52120.99115.5377.9176.0855.5640.8523.7514.9711.7911.3310.5710.208.797.266.997.267.466.447.416.817.187.35NANANA
Operating Lease Liability Noncurrent 68.70NANANA55.80NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Stockholders Equity 25973.1024904.4024017.9023495.2022664.0021438.8020687.8019914.7018768.8017258.0015127.3011977.0011025.3010125.509057.4012133.0011089.7010504.409755.909444.708757.307868.307186.436567.646144.086051.595520.744866.024449.244491.254076.513765.083654.843296.873338.462971.432542.322551.792368.842211.251952.081690.171493.341406.351245.38806.02594.66504.02485.73428.25478.03518.09527.82348.06371.22386.27
Additional Paid In Capital 11354.0011251.5010888.5010597.709949.309518.209120.208754.108087.507919.307225.806887.806716.206592.806263.005211.404428.604388.404263.604160.903911.603841.173712.603611.603512.833570.673449.623190.883029.993314.983156.943049.653099.532880.113118.972812.572404.122423.432342.842236.932045.861882.421827.471826.081763.511795.291775.861760.941754.821643.771630.361609.181575.78NANANA
Retained Earnings Accumulated Deficit 27260.3026100.7025092.9024124.5023306.7022109.6020793.9019941.8018968.3016739.3015107.1012008.2010893.009743.808901.708004.407379.806587.805918.205725.105254.304433.903839.183287.772946.732773.212384.901997.151748.221495.111230.301018.44852.70697.71487.31292.67255.38145.2165.49-27.25-92.69-189.50-330.80-418.18-517.05-987.46-1178.93-1255.67-1267.32-1213.88-1151.52-1089.01-1045.56NANANA
Accumulated Other Comprehensive Income Loss Net Of Tax -80.90-176.80-197.70-181.60-238.80-275.10-223.80-170.10-26.209.5015.7016.2029.3030.8035.50-9.1021.1016.5015.802.80-12.30-10.52-11.61-15.590.6423.842.35-5.88-12.84-2.905.204.368.577.7219.1547.9052.2526.894.261.47-1.19-2.85-3.43-1.64-1.17-1.90-2.37-1.34-1.86-1.73-0.90-2.17-2.49NANANA
Treasury Stock Value NANANANANA9914.009002.608611.208260.907410.207221.406935.306613.306242.006142.901073.80739.90488.40441.80444.20396.40396.37353.85316.24316.24316.24316.24316.24316.24316.05316.05307.48306.07288.78287.08181.82-169.5343.85-43.85NA0.00NANANANANANANANANANANANANANANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value NA207.40208.00237.40NA171.10166.00165.90NA136.40135.90135.60NA104.60105.20108.00NA112.70109.20114.80NA116.50113.1085.80NANANANANANANANANANANANA82.6174.5672.1682.9855.2946.0845.1753.5530.6720.6619.4023.4515.8413.3812.4914.90NANANA8.83

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Net Cash Provided By Used In Operating Activities 1089.701114.301022.401367.601719.90628.90564.402101.702372.503413.60626.70668.501231.00-254.30943.40698.00787.40557.30188.30897.00728.83452.96394.56618.74566.95414.83-30.57355.90377.88651.03415.1529.34281.82892.85243.61-87.50198.28163.56327.7953.53276.7892.45128.1686.2593.19-2.38-78.38-87.04-50.32-46.73-34.05-10.58-43.73161.50-11.85-9.58
Net Cash Provided By Used In Investing Activities -66.20-496.30-2386.90-235.70-1857.70192.30-413.90-1705.30-2012.70-2438.80125.80-1059.00-305.00-775.801453.40-443.20-208.70-207.00-836.00-776.10-265.91-286.71-484.97-425.41-335.75-358.88-170.41-140.14-271.36-405.85-326.01-43.69-123.30-283.17-371.65-129.4856.65-123.07-118.12-236.23-109.95-214.45116.63-147.6991.10-48.75-139.1915.77-33.91-0.90142.9420.35-351.7450.173.82-136.40
Net Cash Provided By Used In Financing Activities -446.10-407.30-614.20-322.50-247.60-725.00-101.1064.70-906.60385.40-118.20-366.40-305.30612.00-2612.80335.60-345.70-11.00-15.30119.90-83.033.71-11.2113.43-210.53-8.20133.5260.81-491.6828.68-46.84-190.54-4.01-345.6510.6976.17-252.765.93-71.39108.95105.563.53-43.4811.52-73.01-1.81-5.08-17.75361.44-0.2810.0513.04182.761.612.7256.22

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Net Cash Provided By Used In Operating Activities 1089.701114.301022.401367.601719.90628.90564.402101.702372.503413.60626.70668.501231.00-254.30943.40698.00787.40557.30188.30897.00728.83452.96394.56618.74566.95414.83-30.57355.90377.88651.03415.1529.34281.82892.85243.61-87.50198.28163.56327.7953.53276.7892.45128.1686.2593.19-2.38-78.38-87.04-50.32-46.73-34.05-10.58-43.73161.50-11.85-9.58
Net Income Loss 1159.601007.80968.40817.801197.101315.70852.10973.502229.001632.203098.901115.201149.20842.10897.30624.60792.00669.60193.10461.10820.40594.65551.41477.98173.52388.32387.74248.93253.12264.80196.22165.74154.99210.40194.6476.02110.1879.7292.7365.4496.81141.3187.3898.87470.41191.4776.7411.65-53.44-62.37-62.51-43.45-14.60-33.88-25.47-30.52
Depreciation Depletion And Amortization 113.00105.40103.1099.50100.1092.6074.4074.3074.5073.2071.1067.4061.7059.3058.8056.1054.3052.9052.1051.0042.7635.4433.6436.3634.5137.7235.1338.1228.9027.8425.0322.9822.9120.6715.3016.0314.1314.0113.0211.5311.2910.809.709.419.789.339.428.427.948.287.906.986.094.894.524.18
Increase Decrease In Accounts Receivable 82.70463.502.70-210.10-219.60386.90322.40-1197.50584.50-1541.002825.6058.3080.801228.20-121.90169.0012.20204.10150.70106.1040.30163.7095.31-30.412.89126.9095.00137.93-32.25-108.10-113.25397.4328.4844.1997.69321.0690.1433.33-153.5792.53-101.05116.8173.38109.5291.85165.89197.03135.3135.78-6.12-3.59-4.9610.82-12.9123.346.29
Increase Decrease In Inventories 47.3077.20100.4046.80144.30223.50240.1088.60163.70109.10-31.30252.80127.00169.00162.6070.80108.3059.00109.6058.60106.2899.5293.3488.7678.5584.1081.8069.7450.0726.8210.6262.2630.3731.6143.925.939.9813.6221.7515.5511.215.6013.5617.58NANANANANANANANANANANANA
Share Based Compensation 240.40203.90202.00238.70232.00166.30159.80166.90188.40136.90145.50130.90121.50101.20103.50105.80133.50117.10105.80107.90126.75111.44106.8082.42127.13125.10121.26133.79154.56131.38131.69142.25158.39102.6094.26103.7681.4568.1064.8381.4155.1845.7444.4453.0330.7720.5419.6123.2415.5313.3612.4014.8013.578.798.718.83

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Net Cash Provided By Used In Investing Activities -66.20-496.30-2386.90-235.70-1857.70192.30-413.90-1705.30-2012.70-2438.80125.80-1059.00-305.00-775.801453.40-443.20-208.70-207.00-836.00-776.10-265.91-286.71-484.97-425.41-335.75-358.88-170.41-140.14-271.36-405.85-326.01-43.69-123.30-283.17-371.65-129.4856.65-123.07-118.12-236.23-109.95-214.45116.63-147.6991.10-48.75-139.1915.77-33.91-0.90142.9420.35-351.7450.173.82-136.40
Payments To Acquire Productive Assets 251.40176.00113.00178.20152.20142.50153.60141.80154.90133.20148.50115.30161.40153.20129.90170.10139.00121.7094.6074.3085.46106.25112.0279.38107.6659.6554.8550.46150.46118.56138.84104.09177.78146.10239.89114.16117.5479.7770.8764.8268.9831.6934.4521.2015.1610.2512.8711.0511.298.9014.8622.1732.2622.1022.5822.74

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Net Cash Provided By Used In Financing Activities -446.10-407.30-614.20-322.50-247.60-725.00-101.1064.70-906.60385.40-118.20-366.40-305.30612.00-2612.80335.60-345.70-11.00-15.30119.90-83.033.71-11.2113.43-210.53-8.20133.5260.81-491.6828.68-46.84-190.54-4.01-345.6510.6976.17-252.765.93-71.39108.95105.563.53-43.4811.52-73.01-1.81-5.08-17.75361.44-0.2810.0513.04182.761.612.7256.22
Payments For Repurchase Of Common Stock 289.00546.50688.80710.70431.10934.60359.00358.10866.90166.40305.20306.90381.1092.105052.90320.70246.5019.400.0010.000.024.380.000.000.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

    2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31
Revenues 3434.303362.703158.103162.103414.402936.202857.202965.104951.703452.805138.502528.702422.902294.001952.001828.202169.502048.401933.701711.801927.801663.501608.021511.481582.451500.671470.121318.991226.831220.121212.631200.851098.081137.42998.62869.61802.33725.79665.70625.74610.41597.03457.64439.66414.60427.69304.40231.79122.98102.83107.81112.20133.68105.98115.89103.53
Revenue From Contract With Customer Excluding Assessed Tax 3434.303362.703158.103162.103414.402936.202857.202965.104951.703452.805138.502528.702422.902294.001952.001828.202169.502048.401933.701711.801927.801663.501608.021511.501582.401500.671470.121319.001226.831220.121212.631200.851098.081137.42998.62869.61802.33725.79665.70625.74610.41597.03457.64439.66414.60427.69304.40231.79122.98102.83107.81112.20133.68105.98115.89103.53
Sanofi, Sales Based Milestones, Sanofi Collaboration Agreement Immunooncology NANA0.00100.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sanofi, Regulatory Milestone, Sanofi Collaboration Agreement Immunooncology NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sanofi, Sales Based Milestones, Sanofi Collaboration Agreement Immunooncology NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sanofi, Regulatory Milestone, Sanofi Collaboration Agreement Immunooncology, Subsequent Event NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sanofi, Sales Based Milestones, Sanofi Collaboration Agreement Immunooncology, Subsequent Event NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sales Milestone Three, Sanofi Collaboration Agreement Antibody NANANANANANANA50.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Clinical Proof Of Principle Milestone, Alnylam, Alnylam Pharmaceuticals Inc. Collaboration Agreement NA100.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Development Milestone, Sonoma Biotherapeutics Inc, Sonoma Biotherapeutics Inc Collaboration Agreement NANANA45.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sales Based Milestone Two, Sanofi, Sanofi Collaboration Agreement Immunooncology NA0.000.0035.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sales Based Milestone One, Sanofi, Sanofi Collaboration Agreement Immunooncology NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Collaboration Revenue 1370.001438.301316.701378.10-1268.301050.601043.601232.50-1011.901073.90954.70754.40-508.70653.20513.30528.30NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product 1851.801786.101772.101668.001699.301801.401754.401638.603975.202279.904137.801724.301621.801482.201226.901236.701286.401238.301205.301104.401096.421025.49996.38987.90978.75957.37924.13NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Product And Service Other 212.50138.3069.30116.00127.7084.2059.2094.0086.2099.0046.0050.00123.40158.60211.8063.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Amounts Recognized In Connection With Up Front Payments, Sanofi Collaboration Agreement Immunooncology, Other Operating Income Expense NANANANA0.000.0017.0018.1010.20-47.7020.7022.90153.6020.0020.5016.50NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Next Generation Covid Antibodies, B A R D A Other Transaction Agreement, Collaboration Revenue NA34.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Other, Roche Collaboration Agreement, Collaboration Revenue -3.80-5.70-3.80NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Other Collaboration Agreements, Sanofi Collaboration Agreement Antibody, Collaboration Revenue NANANANA0.00-0.2028.90NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Regenerons Share Of Commercial Expenses, Sanofi Collaboration Agreement Immunooncology, Selling General And Administrative Expenses NANANANA0.000.00-10.70-9.20-8.30-9.40-10.90-7.70-7.40-6.10-4.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Regenerons Share Of Research And Development Expenses, Sanofi Collaboration Agreement Antibody, Research And Development Expense NANANANANANA-15.60-9.70-13.90-10.30-10.60-11.90-18.50-17.50-24.90-16.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement For Manufacturing Of Commercial Supplies, Sanofi Collaboration Agreement Antibody, Collaboration Revenue 107.00151.50192.60161.90166.90160.50145.50160.80127.60144.70110.90105.6093.0094.30100.6080.10NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement For Manufacturing Of Ex Commercial Supplies, Sanofi Collaboration Agreement Immunooncology, Collaboration Revenue NANANANANA0.002.602.00NA3.102.704.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement Of Commercialization Related Expenses, Sanofi Collaboration Agreement Antibody, Selling General And Administrative Expenses 150.40135.50130.90117.60126.30108.60110.8091.70103.6079.0078.3060.4099.0083.2086.0091.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement Of Commercialization Related Expenses, Sanofi Collaboration Agreement Immunooncology, Selling General And Administrative Expenses NANANANA0.000.0022.4019.0027.6022.8020.7018.5025.5014.5014.3010.40NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement Of Research And Development Expenses, Sanofi Collaboration Agreement Antibody, Research And Development Expense NANANANANANA52.7036.5053.6045.2046.5030.1052.3045.5051.3077.60NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement Of Research And Development Expenses, Sanofi Collaboration Agreement Immunooncology, Research And Development Expense NANANANA0.000.0021.2021.5018.9021.8022.5021.9029.5049.8047.0039.90NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement Of Research And Development Expenses Net Of Obligation For Share Of R D Expenses, Sanofi Collaboration Agreement Antibody, Research And Development Expense -17.00-25.80-14.50-26.40-16.60-4.3037.1026.8039.7034.90NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Ronapreve, Roche Collaboration Agreement, Collaboration Revenue 2.100.000.00222.20396.406.408.20216.300.00127.10167.9066.80NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sales Based Milestone Earned, Sanofi Collaboration Agreement Antibody, Collaboration Revenue 0.0050.00NANA50.000.000.0050.000.0050.00NANA0.0050.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Sanofis Shareof Libtayo U. S. Gross Profits, Sanofi Collaboration Agreement Immunooncology, Cost Of Goods Sold NANANANANA0.00-37.80-32.30NA-34.60-34.40-30.40NA-31.50-28.20-26.80NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Share Of Profit Losses In Connection With Commercialization, Sanofi Collaboration Agreement Antibody, Collaboration Revenue NA863.00751.10636.50NA551.10496.60415.30NA387.00327.60260.60NA212.80171.90170.90NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
EYLEAHD,US NA42.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Evkeeza,US 24.0019.1019.3014.9015.4013.6011.108.509.306.602.000.50NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Eylea Net Product Sales,US 1337.501448.201500.101433.801496.401629.401621.201517.601547.201473.401424.701347.001343.201318.301113.701172.001222.101187.701160.301074.101078.871021.78992.00984.00974.77953.28919.47NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Inmazeb,US 62.103.302.202.200.003.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
L I B T A Y O Net Product Sales,US 154.80144.10130.20109.70110.0094.7090.9078.9080.8078.4078.0069.1074.1071.6063.3061.7060.5047.6040.8026.8014.800.000.000.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
L I B T A Y O Net Product Sales, Rest Of World NA88.3079.8067.2042.0031.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Praluent Net Product Sales,US 61.3040.4040.5040.2035.5029.7031.2033.6040.0044.8041.9043.3055.2048.5047.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Net Profit In Connection With Commercialization, Non Us, Bayer Collaboration Agreement, Collaboration Revenue 345.40349.90349.50331.60324.00315.30339.70338.40353.90351.00335.40308.90335.30287.90230.90253.80NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
One Time Payment In Connection With Change In Japan Arrangement, Non Us, Bayer Collaboration Agreement, Collaboration Revenue NANANANA0.000.000.0021.90NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Regenerons Obligation Of Research And Development Expenses Net Of Reimbursement Of Research And Development Expenses, Non Us, Bayer Collaboration Agreement, Research And Development Expenses And Reduction Of Research And Development Expense -8.90-9.70-12.00-13.406.407.102.900.30NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Regenerons Share Of Research And Development Expenses, Non Us, Bayer Collaboration Agreement, Research And Development Expense NANANANA-11.90-4.70-6.90-10.80-9.50-8.00-10.90-12.50-9.50-12.90-5.30-8.10NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement For Manufacturing Of Commercial Supplies, Non Us, Bayer Collaboration Agreement, Collaboration Revenue 31.4027.2027.2025.3031.1017.5017.8025.0018.5014.0013.7013.9025.3012.0013.3027.60NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Reimbursement Of Research And Development Expenses, Non Us, Bayer Collaboration Agreement, Research And Development Expense NANANANA18.3011.809.8011.1010.9014.509.9010.8012.4011.5010.8012.00NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
Share Of Profit Losses In Connection With Commercialization, Non Us, Sanofi Collaboration Agreement Immunooncology, Collaboration Revenue NANANANANA0.003.902.80NA-3.00-3.50-6.10NA-4.70-6.40-6.20NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
US NANANANA1699.301801.401754.401638.603975.202279.904137.801724.301621.801482.201226.901236.70NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Other Comprehensive Income Loss Net Of Tax
Expenses
Income Tax Expense Benefit
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Operating Lease Right Of Use Asset
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Operating Lease Right Of Use Asset
Liabilities
Operating Lease Liability
Current Liabilities
Taxes Payable Current
Noncurrent Liabilities
Operating Lease Liability Noncurrent
Stockholders Equity
Accumulated Other Comprehensive Income Loss Net Of Tax
CashFlow
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInOperatingActivities
Increase Decrease In Prepaid Deferred Expense And Other Assets
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInFinancingActivities
Net Cash Provided By Used In Financing Activities
Shares
Treasury Stock Shares
OperatingLeaseLiability
Operating Lease Liability Current
NonoperatingIncomeExpense
Interest Expense
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Due Year Four
FiniteLivedIntangibleAssets
Finite Lived Intangible Assets Accumulated Amortization
InventoryNet
Inventory Finished Goods Net Of Reserves

Line plots across dimensions of each concept


us-gaap:SharesOutstanding
us-gaap:StatementEquityComponents
(None,)
Shares Outstandingus-gaap: Statement Equity Components
dei:EntityCommonStockSharesOutstanding
us-gaap:StatementClassOfStock
(None,)
Entity Common Stock Shares Outstandingus-gaap: Statement Class Of Stock
TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical
('regn:LIBTAYONetProductSales', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical
(None, 'US')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:SanofiCollaborationAgreementAntibody', 'regn:CollaborationRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:RocheCollaborationAgreement', 'regn:CollaborationRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:SanofiCollaborationAgreementImmunooncology', 'us-gaap:SellingGeneralAndAdministrativeExpenses')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:SanofiCollaborationAgreementAntibody', 'us-gaap:ResearchAndDevelopmentExpense')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'us-gaap:NonUs', 'regn:BayerCollaborationAgreement', 'regn:CollaborationRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'us-gaap:NonUs', 'regn:BayerCollaborationAgreement', 'us-gaap:ResearchAndDevelopmentExpense')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:CostOfGoodsAndServicesSold
us-gaap:ProductOrService
(None,)
Cost Of Goods And Services Soldus-gaap: Product Or Service
us-gaap:ResearchAndDevelopmentExpense
us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
('regn:AlnylamPharmaceuticalsInc.CollaborationAgreement', None)
Research And Development Expenseus-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AccountsReceivableNetCurrent
us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject
(None,)
Accounts Receivable Net Currentus-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project
us-gaap:EquitySecuritiesFvNi
regn:ClassificationOfInvestment, us-gaap:FairValueByMeasurementFrequency
(None, 'us-gaap:FairValueMeasurementsRecurring')
Equity Securities Fv Niregn: Classification Of Investment, us-gaap: Fair Value By Measurement Frequency
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueInputsLevel2', 'us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Fair Value Hierarchy Level, us-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
('us-gaap:FairValueMeasurementsRecurring', None)
Available For Sale Securities Debt Securitiesus-gaap: Fair Value By Measurement Frequency, us-gaap: Financial Instrument
us-gaap:FiniteLivedIntangibleAssetsNet
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
(None,)
Finite Lived Intangible Assets Netus-gaap: Finite Lived Intangible Assets By Major Class
us-gaap:EquitySecuritiesFvNi
regn:ClassificationOfInvestment, us-gaap:FairValueByMeasurementFrequency
(None, 'us-gaap:FairValueMeasurementsRecurring')
Equity Securities Fv Niregn: Classification Of Investment, us-gaap: Fair Value By Measurement Frequency
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument
(None,)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Financial Instrument
us-gaap:LongTermDebt
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
(None, 'us-gaap:SeniorNotes')
Long Term Debtus-gaap: Debt Instrument, us-gaap: Longterm Debt Type
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical
('regn:LIBTAYONetProductSales', None)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical
(None, 'US')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:SanofiCollaborationAgreementAntibody', 'regn:CollaborationRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:RocheCollaborationAgreement', 'regn:CollaborationRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:SanofiCollaborationAgreementImmunooncology', 'us-gaap:SellingGeneralAndAdministrativeExpenses')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'regn:SanofiCollaborationAgreementAntibody', 'us-gaap:ResearchAndDevelopmentExpense')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'us-gaap:NonUs', 'regn:BayerCollaborationAgreement', 'regn:CollaborationRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProject, us-gaap:IncomeStatementLocation
(None, 'us-gaap:NonUs', 'regn:BayerCollaborationAgreement', 'us-gaap:ResearchAndDevelopmentExpense')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Statement Geographical, us-gaap: Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project, us-gaap: Income Statement Location